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INTRODUCTION
As a consequence of socio-economic and political crises 
in Northern and Sub-Saharan Africa, Eastern Europe, 
the Middle-East and East Asia in recent years, Italy has 
become a land of immigration from these geographical 
areas. In spite of the intermediate or high endemicity level 
of hepatitis B virus (HBV) infection in their countries of 
origin, the majority of immigrants coming to Italy are un-
aware of their HBV serological status. Once in Italy, this 
immigrant population, prevalently young and with insuf-
ficient income, is socially disintegrated due to language, 
cultural and socio-economic barriers and has limited ac-
cess to the healthcare services (Coppola et al., in press; 
Fasano et al., 2013; Kim, et al., 2014; Majori et al., 2008; 
Sagnelli C, et al., 2014; Sagnelli C et al., 2015; Sagnelli E, 
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et al., 2014b,c; Sagnelli et al., 2012a; Spada et al., 2011).
Pregnancy and the future delivery of the baby, however, 
induce pregnant immigrants to refer to a hospital of the 
Italian National Healthcare System, where screening for 
serological markers of HBV infection is always performed 
in accordance with the strategies of the universal an-
ti-HBV prophylaxis of newborn babies in Italy. 
Only a few studies have been published to date on chron-
ic HBV infection in pregnant immigrants in Italy, mostly 
concerning the results of screening for serum hepatitis 
B antigen (HBsAg) at delivery, with HBsAg prevalences 
ranging from 2.5% to 5.9%, most probably reflecting a 
different composition of the study samples investigat-
ed (Bonura et al., 2005; Spada et al., 2011; Stroffolini et 
al., 2003). To the best o f  o u r  knowledge, no further 
informative investigation has been reported more recent-
ly. The immigrant population has changed a great deal in 
Italy because of an increased silent massive immigration 
from East Asia, Ukraine and Romania and because of 
wars involving countries in Northern and Sub-Saharan 
Africa and the consequent increase in the number of refu-
gees from these geographical areas.
This paper analyzes the demographic, laboratory and 
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The aims of the study were to estimate the clinical impact of HBV infection in pregnant immigrants and 
their family members and to identify a useful approach to managing the healthcare of HBsAg-positive 
immigrants.
Included in this study were 143 HBsAg-positive pregnant immigrants of the 1,970 from countries with 
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stay in Italy 5.0±4.1 years; 56.5% were unaware of their HBsAg positivity. HBV DNA was detected in 74.5% 
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clinical data of the 143 HBsAg-positive pregnant immi-
grants of the 1,970 who delivered in 2012/2013 at 8 Ital-
ian hospitals in different cities in Northern, Central and 
Southern Italy (Brescia, Florence, Rome, Viterbo, Caserta, 
Naples, Foggia, Catania). 
The paper also describes the first screening performed in 
Italy to detect HBV infection in family members of the 
HBsAg-positive pregnant immigrants. The HBsAg-posi-
tive pregnant immigrants and their HBsAg-positive fam-
ily members were counselled on the prophylactic mea-
sures to prevent the transmission of HBV infection and 
were referred for clinical investigation free of charge to 
the unit of infectious diseases of the hospital where im-
migrant women delivered. All newborn babies un derwent 
HBV immunoprophylaxis.
MATERIALS AND METHODS
The present study regards the 143 consecutive HB-
sAg-positive pregnant women out of the 1,970 pregnant 
immigrants observed during pregnancy or at the time of 
delivery in 2012/2013 at one of the 8 hospitals in differ-
ent cities in Northern, Central and Southern Italy (Brescia, 
Florence, Rome, Viterbo, Caserta, Naples, Foggia, Cata-
nia). These pregnant migrants came from countries with 
an intermediate or high HBV endemicity, mostly from 
Northern and Sub-Saharan Africa, Eastern Europe, the 
Middle East and East Asia.
For each pregnant immigrant a pre-coded questionnaire 
reporting the demographic, epidemiological, laboratory 
and clinical data was filled out by the physician in care 
at the first observation. One hundred and seventy-two 
family members of 96 HBsAg-positive pregnant immi-
grants were screened for HBsAg on a voluntary basis. 
All HBsAg-positive pregnant immigrants and their HB-
sAg-positive family members were referred for a clinical 
and, if necessary, therapeutic follow-up at the Unit 
of Infectious Diseases of the hospital where the women 
delivered.
The study was approved by the Ethics Committee of 
the Azienda Ospedaliera Sant’Anna e San Sebastiano of 
Caserta (number protocol 222/2013). All the procedures 
used in the study complied with the standards on hu-
man experimentation of the relative Ethics Committees 
and with the Helsinki Declaration of 1975, revised in 1983. 
Each subject enrolled in the present study signed their 
informed consent in accordance with the rules of the local 
Ethics Committees.
Serum samples were tested for HBsAg, hepatitis B e anti-
gen (HBeAg) and for the antibody to HBeAg (anti-HBe) by 
commercial enzyme immunoassays (Abbott Laboratories, 
North Chicago, IL, USA). The antibody to the hepatitis 
delta antigen (HDV-Ab) was sought using a commer-
cial enzyme immunoassay (DiaSorin, Saluggia, VC, It-
aly). Plasma HBV DNA was sought by real-time poly-
merase chain reaction as previously described (Coppola 
et al., 2010; Coppola et al., 2013). Liver function tests were 
performed using routine methods. Continuous variables 
were summarized as mean and standard deviation, and 
categorical variables as absolute and relative frequencies. 
Differences in the mean values were evaluated by the 
Student t-test, and the chi-squared test was applied to 
categorical variables. A p value <0.05 was considered to 
be statistically significant.
RESULTS
Of the 143 HBsAg-positive pregnant immigrants investi-
gated, 53 were from Eastern Europe, 35 from East Asia, 
48 from Sub-Saharan Africa, 5 from Northern Africa and 2 
from South America. The demographic characteristics of 
these 143 and of the three largest geographical subgroups 
are shown in Table 1. The median age was 31.0±12.1 years, 
with only slight differences in the three largest subgroups 
Table 1 - Demographic and epidemiological characteristics of the 143 HBsAg-positive pregnant immigrants, and the data for the three 
largest subgroups.
Total Eastern
Europe
East Asia Sub-Saharan
Africa
HBsAg positive, N. *143 53 35 48
Age, years, M±SD 31±12.1 32.2±17.8 30.8±6 29.9±4.6
At their first pregnancy, N. (%) 80 (55.9) 36 (67.9) A 22 (62.9) C 15 (31.3) B D
Living in Italy for years, M±SD 5.0±4.1 5.4±3.9 E 7.3±5.3 F G 4.4±3.1 H
HBsAg positivity before pregnancy:
61 (43.3) 19 (35.8) I 20 (60.6) J 20 (41.7)known, N. (%)
unknown, N. (%) 80 (56.7) 34 (64.2) 13 (40.6) 28 (58.3)
missing, N. 2 0 2 0
HBsAg positivity before pregnancy,
known for years, M±SD 6.0±5.6 5.9±6.7 K M 8.8±5.8 L 2.4±2.3 N
HBsAg positivity known before pregnancy,
pregnancy:
20 (32.8) 8 (42.1) 4 (20) 6 (30)with chronic hepatitis B, N. (%)
asymptomatic carriers, N. (%) 41 (67.2) 11 (57.9) 16 (80) 14 (70)
*Only 5 pregnant immigrants were from Northern Africa and 2 from South America; consequently these subcontinents are not included in this table. 
A vs B: p=0.003; C vs D: p=0.003; E vs F: p=0.0001; G vs H: p=0.0001; I vs J: p=0.02; K vs L: p=0.04; M vs N: p=0.0001.
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(Table 1). The mean length of the stay in Italy was longer in 
pregnant women from East Asia (7.3±5.3 years) compared 
to those from Eastern Europe (5.4±3.9) or Sub-Saharan 
Africa (4.4±3.1, p=0.0001). Of the 143 pregnant women, 80 
(55.9%) were at their first pregnancy, a prevalence higher 
in the Eastern Europe (67.9%) and East Asia (62.9%) sub-
groups than in the Sub-Saharan Africa (31.3%, p<0.0001) 
subgroup. Only 61 (43.5%) of the pregnant immigrants 
knew they were HBsAg chronic carriers at the time they 
were tested, a percentage higher in the East Asia subgroup 
(60.6%) than in those from Sub-Saharan Africa (41.7%) 
or Eastern Europe (35.8%, p=0.02) (Table 1). In addition, 
pregnant immigrants in the East Asia subgroup knew of 
their HBsAg positivity for longer than those in the Eastern 
Europe (8.8±5.8. years vs 5.9±6.7, p=0.04) or Sub-Saharan 
Africa (2.4±2.3; p=0.0001) subgroups. Also, the compar-
ison between the Eastern Europe and Sub-Saharan Afri-
ca subgroups showed a statistically significant difference 
(p=0.0001) (Table 1). Twenty (32.8%) of the 61 pregnant im-
migrants who knew they were chronic carriers knew they 
had chronic hepatitis B, and 41 (67.2%) knew they were 
asymptomatic HBV carriers (Table 1). Table 2 shows the 
initial virological data of the 143 HBsAg-positive pregnant 
immigrants and of those in the three largest geographical 
subgroups. HBV DNA was detected in 73 (73.7%) of the 99 
HBsAg-positive pregnant women tested, with wide varia-
tions in the geographical subgroups: 83.3% in the Eastern 
Europe subgroup versus 72.2% (p<0.002) in the East Asia 
and 51.3% (p<0.0006) in the Sub-Saharan subgroup. Of 
the 73 HBV-DNA-positive pregnant immigrants, an HBV 
DNA serum level ≥2000 IU/mL, indicating active HBV rep-
lication, was detected in 47.8% of the cases, whereas lower 
levels suggestive of an inactive HBV carriage were detect-
ed in the remaining 52.2% (Table 2).
HBeAg was detected in 19.3% of the HBsAg-positive preg-
nant immigrants tested, with substantial differences in 
the geographical subgroups: 38.5% in those from East 
Asia versus 20% in those from Eastern Europe and 4% 
(p=0.001) in those from Sub-Saharan Africa (Table 2).
Due to the strong reduction in HDV endemicity in Italy 
in the latter two decades, antibodies to HDV-Ag are infre-
quently determined in Italian hospitals, as in hospitals in 
other western countries with low diffusion of HDV infec-
tion (Vergani et al., 2008). In the present study, HDV-Ab 
was determined in nearly one third of the HBsAg-positive 
pregnant immigrants and detected in 10% of cases.
Each baby born of an HBsAg-positive immigrant mother 
started passive/active HBV immunoprophylaxis at birth, 
whereas those born of an HBsAg-negative mother started 
active immunoprophylaxis at the third month. One hun-
dred and twenty-two family members of 96 HBsAg-posi-
tive pregnant immigrants were investigated, mostly hus-
bands or children born of previous pregnancies, and 54 
(31.4%) were found to be HBsAg positive. This prevalence 
ranged from 30 to 38.7% in the three largest geographical 
subgroups.
Table 2 - Laboratory data of the 143 HBsAg-positive pregnant immigrants, and the data for the three largest subgroups.
Total Eastern
Europe
East Asia Sub-Saharan
Africa
HBsAg-positive pregnant 
women, N.
143* 53 35 48
HBeAg, N. (%):
23 (19.3) 9 (20) 10 (38.5) A 3 (7.1) BPositive
Negative 96 (80.7) 36 (80) 16 (61.5) 39 (92.9)
Missing, N. 24 8 9 6
HBeAb, N. (%):
(65.7) 38 (82.6) C 15 (57.7) DE 38 (90.5) FPositive
Negative 24 (16.8) 8 (17.4) 11 (42.3) 4 (9.5)
Missing, N. 25 9 9 6
HBV DNA, N. (%):
73 (73.7) 33 (83.3) G 13 (72.2) 22 (51.3) HPositive
Negative 26 (26.3) 3 (8.3) 5 (27.8) 17 (43.6)
Missing, N. 44 17 17 9
HBV DNA IU/mL, M±SD
1.3E7±5E7 1.2E7±4.2E7 3.9E7±8.8 E7 1.6E6±1.3E6
HBV DNA IU/mL, N. (%):
≤2000 IU/mL
36 (52.2) 18 (58.1) 5 (38.4) 10 (50)
>2000 IU/mL 33 (47.8) 13 (41.9) 8 (61.5) 10 (50)
Missing, N. 4 2 0 2
ALT, IU/mL, M±SD 1.0±1.5 1.6±2.2 1.7±0.6 1.3±0.7
 
*Only 5 pregnant immigrants were from Northern Africa and 2 from South America; consequently, these subcontinents are not included in this table.  
A vs B: p=0.001; C vs D: p=0.02; E vs F: p=0.001; G vs H: p=0.0006.  
x u.n.v. times upper normal value.
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DISCUSSION
The number of pregnant immigrants harbouring chron-
ic HBV infection observed in the present study calls for 
simplified access of this category to the clinical structures 
of the National Healthcare System not only for assistance 
in pregnancy and delivery, but also for their clinical as-
sessment and follow-up. In fact, HBsAg-positive pregnant 
immigrants require a thorough evaluation of their clinical 
condition and in some cases long-term observation in-
cluding possible anti-HBV treatment (Howell et al., 2014; 
Nguyen et al., 2014; Vallet-Pichard et al., 2014). Delivery is 
an appropriate time to offer screening for HBV markers to 
the family members of the HBsAg-positive pregnant im-
migrants, nearly one third of whom were found to be HB-
sAg-positive in the present investigation. This emphasizes 
the strong epidemiological impact of vertical and family 
transmission of HBV in geographical areas with a high or 
intermediate HBV endemicity. This opportunity should 
not be missed since HBV chronic carriers are at risk of de-
veloping a severe liver disease and even hepatocellular car-
cinoma (HCC) (Howell et al., 2014; Ladep et al., 2014; Liu 
et al., 2014), and of transmitting HBV infection to HBsAg/
anti-HBs-negative individuals (Kubo et al., 2014; Sagnelli 
et al., 2012b; Sellier et al., 2014).
As in the case of the HBsAg-positive pregnant immigrants, 
after a preliminary assessment of their clinical condition, 
all HBsAg-positive family members should receive coun-
selling on HBV infection, its routes of transmission and its 
prevention. These HBsAg-positive family members should 
also undergo a clinical assessment and, when appropri-
ate, a follow-up including possible anti-HBV treatment. 
Most of the HBsAg-positive pregnant immigrants in this 
study had detectable HBV DNA, a sign of HBV replication, 
half of them with HBV DNA serum levels ≥2000 IU/mL, a 
viral load considered to be associated with chronic liver 
disease. 
In addition, one fifth of the HBsAg-positive pregnant immi-
grants in the present study were HBeAg positive, a clinical 
condition associated with a more frequent and rapid pro-
gression towards a severe liver disease and HCC (Sagnelli 
et al., 1983; Vallet-Pichard et al., 2014). The clinical pre-
sentation of our 143 HBsAg-positive pregnant immigrants 
is a strong warning for the Italian Healthcare Authorities 
to devise simplified access to allow HBsAg-positive immi-
grants to be followed up in qualified clinical centers, free 
of charge and with reduced bureaucratic procedures.
The limitations of this study are the moderate number 
of HBsAg positive mothers and of their family members 
investigated and the high number of missing for same 
laboratory data (HBeAg and HBV DNA), in part due to 
the moderate compliance of some pregnant women to 
be followed up at the Unit of Infectious Diseases of 
the hospital where they had delivered. The model used, 
however, allowed us to assess the clinical condition of 143 
HBsAg-positive pregnant immigrants, 80 of whom were 
unaware of their HBsAg positivity, and of 53 HBsAg-posi-
tive family members, all unaware of their virological con-
dition. 
In addition, the model made it possible for all HBsAg-pos-
itive pregnant immigrants and their HBsAg-positive fam-
ily members to have easy access to the clinic of infectious 
diseases of the hospital where the pregnant immigrants 
delivered, where they received counselling on HBV infec-
tion and its prevention and underwent a complete clini-
cal evaluation. The data from the present study strongly 
emphasize the need for active continuous screening to 
identify the HBsAg-positive subjects in the immigrant 
populations, particularly those from Eastern Europe and 
Sub-Saharan Africa, who more frequently than those from 
East Asia were unaware of their HBsAg positivity. Our 
model, validated in the present study, can be proposed to 
the Italian Healthcare Authorities for nationwide applica-
tion. 
In good agreement with international recommendations 
(Weinbaum CM 2008), the data from the present study 
emphasize the need for universal screening for HBV in-
fection in people from countries with a HBsAg prevalence 
higher than 2% and remind the Italian healthcare author-
ities to carry out extensive screening and educational pro-
grams for these populations.
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